Chemoradiation for Esophageal Cancer

Mariela A. Blum, Takashi Taketa, Kazuki Sudo, Roopma Wadhwa, Heath D. Skinner, Jaffer A. Ajani

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Esophageal cancer management is based on baseline clinical stage, location of the tumor, and associated comorbid conditions. In patients with localized esophageal cancer (LEC) with technically resectable tumors and who are medically fit for surgery, the current recommendation is trimodality therapy (chemoradiation followed by surgery). Bimodality therapy (definitive chemoradiation) is reserved for patients with cervical esophageal tumors, technically unresectable tumors, for patients who cannot be recommended surgery due to medical comorbidities, or those who decline surgery. Prospective data from 2 studies suggest that definitive chemoradiation may be sufficient for LEC with squamous cell histology; a definite answer, however, is unclear.

Original languageEnglish (US)
Pages (from-to)551-558
Number of pages8
JournalThoracic surgery clinics
Volume23
Issue number4
DOIs
StatePublished - Nov 2013

Keywords

  • Definitive chemoradiation
  • Esophageal carcinoma
  • Multimodality therapy
  • Radiotherapy

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Chemoradiation for Esophageal Cancer'. Together they form a unique fingerprint.

Cite this